NEW YORK, October 6, 2017 /PRNewswire/ --
According to a research report published by Hemp Business Journal and Vote Hemp, the Hemp Food, Body Care, and CBD products lead the U.S. hemp retail market and projected to grow at a five year 22% CAGR. The report estimates that the total retail value of hemp products sold in the U.S. in 2016 was $688 million, and projected to grow to $1.8 billion in sales by 2020. Several categories of products such as shelled seed, protein powder, soaps and lotions have continued to show growing sales. Cannabidiol (CBD) is the part of the cannabis plant that is usually used for medical purposes. Chineseinvestors.com, Inc. (OTC: CIIX), Marijuana Company of America Inc. (OTC: MCOA), AXIM Biotechnologies, Inc. (OTC: AXIM), GW Pharmaceuticals plc (NASDAQ: GWPH), Vitality Biopharma, Inc. (OTC: VBIO).
Growth of the medical cannabis market is expected to accelerate as the products become more popular treatments for various medical applications such as chronic pain, post-traumatic stress disorder (PTSD), sleep disorders, anxiety, nerve pain and others. "The United States constitutes 35% of the global pharmaceutical market, the largest market in the world, and a major driver of the U.S. economy. It is one of many industries that will be impacted by the growth of the legal cannabis market and we are already starting to see that trend in legal medical states where use of key prescription drugs is down by 11%. If cannabis were to be adopted nationally, we would begin to see a trend of patients turning to medical cannabis as a substitute or complement to pharmaceuticals," said Giadha Aguirre De Carcer, CEO and Founder, New Frontier Data.
Chineseinvestors.com, Inc. (OTCQB: CIIX) On October 2nd announced that it has appointed Skin Care Industry veteran and Shanghai beauty influencer, Fannie (Chun Fang) Tang as Marketing Director of its wholly-owned foreign enterprise, CBD Biotechnology Co., Ltd. effective immediately. Ms. Tang will report directly to CBD Biotechnology's CEO, Summer Yun, and will be responsible for developing and implementing branding strategies for CBD Biotechnology's CBD Magic Hemp Series skin care line in China. With over 20 years' experience in the industry, Tang was highlighted in the book entitled Shanghai Beauty 26 as a leading influencer in Shanghai's beauty culture. Ms. Tang served as the CEO of L.D. Waxson Group's China Division until it was acquired in 2012 by India's third largest software services provider, Wipro Limited, for $144 million. L.D. Waxson, a leading skin care company with manufacturing facilities in China and Malaysia, and a strong footprint in Singapore, Malaysia, China, Taiwan, Hong Kong and Thailand, reported revenues of approximately $68m prior to its acquisition in 2012. It's portfolio of brands included the skin care lines Bioessence and Ginvera, and Ebene, a popular healthcare brand.
"With over twenty years of marketing and branding experience in the skin care and cosmetics industry, I believe CBD Biotechnology is extremely fortunate to be working with Ms. Tang," says Yun. "Ms. Tang's concept of 'Beauty Derives from Nature and Creation' aligns with CBD Biotechnology's vision to develop an innovative, natural skin care band. Moreover, Ms. Tang has proven success in the industry in this region. Through her efforts, we are confident that CBD Biotechnology will position itself to become a leader in China's skin care industry."
In September 2017, CBD Biotechnology completed the filing process with the China Food & Drug Administration for its first three products in the CBD Magic Hemp Series line, namely the CBDBIO TECH Brightening and Refreshing Moisturizer, the CBDBIO TECH Perfecting Shield Primer, and the CBDBIO TECH Peptide Collagen Solution, which are expected to be formally launched this month. The CBD Magic Hemp Series skin care line will be marketed through multiple sales channels, including online sales, app sales, and third party distribution relationships with online celebrities and market influencers.
Marijuana Company of America Inc. (OTC: MCOA) delivers all of the benefits of cannabis and hemp to the world through unique marketing and distribution platforms. On September 21, 2017, the company in conjunction with its joint venture partner, Global Hemp Group, Inc. provided an update on the hemp cultivation trials conducted in New Brunswick, Canada. The field portion of this first-year trial is now complete, with results from laboratory analysis of CBD concentrations of the flowers and leaves expected within the next two to four weeks. Next year's production will focus on five experienced farmers cultivating a total of 125 acres. MCOA and GHG has also recruited an agronomist to provide agronomic support to the farmers.
AXIM Biotechnologies, Inc. (OTCQB: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. The company's flagship products include CanChew+®, a CBD-based controlled release chewing gum, CanChew+ 50®, containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx®, a combination CBD/THC gum that will undergo clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. Recently, the company announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/982,610, a patent that claims the use of an ophthalmic solution comprising cannabinoids for the treatment of glaucoma and symptomatic relief of conjunctival inflammation. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from AXIM's patent application, 14/982,610, filed in December 2015.
GW Pharmaceuticals plc (NASDAQ: GWPH) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform. On May 24, 2017, the company and its U.S. subsidiary Greenwich Biosciences, announced that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex®(cannabidiol) in children with Dravet syndrome. Epidiolex, GW's lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders.
Vitality Biopharma, Inc. (OTCQB: VBIO) is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Recently, the company announced the achievement of a biosynthesis breakthrough. Vitality has developed a proprietary biosynthesis technology that can modify cannabinoids in order to create pharmaceutical prodrugs that have no psychoactivity and that are able to provide targeted disease treatment. "With our cannabinoid pharmaceutical program, we are quickly moving from 'bench to bedside,' so it's important to recognize technical milestones like this one that have enabled and sped our progress," said Robert Brooke, CEO of Vitality Biopharma. "Our team first pioneered enzymatic biosynthesis methods for cannabosides and now has made their production far more efficient and scalable."
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information:
These press releases may also interest you